Literature DB >> 1591709

Chromosome abnormalities in low-grade central nervous system tumors.

C A Griffin1, P P Long, B S Carson, H Brem.   

Abstract

Ependymomas, oligodendrogliomas, and low-grade astrocytomas are slow-growing central nervous system (CNS) tumors that occur in both adults and children, whereas craniopharyngiomas and choroid plexus papillomas occur predominantly in children. We examined karyotypes of 32 of these low-grade tumors, including ten oligodendrogliomas, six ependymomas, 11 low-grade astrocytomas, four craniopharyngiomas, and one choroid plexus papilloma. Only normal karyotypes were obtained from 6 oligodendrogliomas. The rest had normal stemlines; three tumors had 45,X,-Y sidelines and one tumor had a sideline of monosomy 22. The most frequent abnormalities in the ependymomas were +7 (three tumors), -21 (two tumors), -22 (two tumors), and del(9)(p22) (two tumors). Gains of chromosome 7 and deletions of 9p were found more often in high-grade gliomas. Seven low-grade astrocytomas had normal stemlines, two had chromosome 7 abnormalities, a pilocystic astrocytoma had +der(15), and one tumor had a -Y sideline. The four craniopharyngiomas and one choroid plexus tumor were all apparently normal. The cytogenetics of low-grade CNS tumors differ from higher grade gliomas in that most low-grade tumors show little deviation from the normal karyotype.

Entities:  

Mesh:

Year:  1992        PMID: 1591709     DOI: 10.1016/0165-4608(92)90235-z

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  16 in total

1.  Infrequency of p53 gene mutations in ependymomas.

Authors:  K L Fink; E J Rushing; S C Schold; P D Nisen
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Recurrent anaplastic ependymoma with an abnormal karyotype and c-myc proto-oncogene overexpression.

Authors:  M Debiec-Rychter; J Lasota; J Alwasiak; P P Liberski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

3.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups.

Authors:  Y Hirose; K Aldape; A Bollen; C D James; D Brat; K Lamborn; M Berger; B G Feuerstein
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.

Authors:  Mariarita Santi; Martha Quezado; Rubin Ronchetti; Elisabeth J Rushing
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 5.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

6.  Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.

Authors:  Samantha J Ward; Katherine Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic Thompson; Thomas S Jacques; Brian Harding; John L Darling; David G T Thomas; Tracy J Warr
Journal:  J Neurooncol       Date:  2010-01-06       Impact factor: 4.130

7.  A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor.

Authors:  Takashi Yokota; Takayuki Tachizawa; Koichi Fukino; Akira Teramoto; Jun Kouno; Koshi Matsumoto; Mitsuru Emi
Journal:  J Hum Genet       Date:  2003-10-18       Impact factor: 3.172

Review 8.  Molecular biology of pediatric gliomas.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 10.  The genetic and epigenetic basis of ependymoma.

Authors:  Stephen C Mack; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2009-06-18       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.